SMARCA4 and neoplasm: Mechanistically, mutated SMARCA4‐induced resistance to ICI has been linked to markedly decreased tumor infiltration of dendritic cells and CD4+ T cells and downregulation of STING, IL1β, and inflammatory cytokines required for efficient recruitment and activity of immune cells, secondary to loss of chromatin accessibility at enhancers of genes responsible for the innate immune response [32].